ISRCTN39643421 https://doi.org/10.1186/ISRCTN39643421

Trial of Short Course Therapy in Elderly Patients with High Grade Non-Hodgkin's Lymphoma

Submission date 19/08/2002	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [_] Results [_] Individual participant data [_] Record updated in last year
Registration date 19/08/2002	**Overall study status** Completed	
Last Edited 08/04/2015	**Condition category** Cancer	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
- - -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
LY/SCT

Study information

Scientific Title
Trial of Short Course Therapy in Elderly Patients with High Grade Non-Hodgkin's Lymphoma

Study objectives
Not provided at time of registration

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Lymphoma (non-Hodgkin's)

Interventions
1. PACEBO Regimen: Adriamycin, cyclophosphamide, etoposide, vincristine, bleomycin, prednisolone and septin, cycle to be repeated every 14 days for four cycles.
2. PMitCEBO Regimen: Mitoxantrone, cyclophosphamide, etoposide, vincristine, bleomycin, prednisolone and septin, cycle to be repeated every 14 days for four cycles.

Intervention Type
Drug

Phase
Not Applicable

Drug/device/biological/vaccine name(s)
PACEBO Regimen: Adriamycin, cyclophosphamide, etoposide, vincristine, bleomycin, prednisolone and septin PMitCEBO Regimen: Mitoxantrone, cyclophosphamide, etoposide, vincristine, bleomycin, prednisolone and septin

Primary outcome measure

Not provided at time of registration

Secondary outcome measures
Not provided at time of registration

Overall study start date
01/01/2000

Completion date
31/12/2005

Eligibility

Key inclusion criteria
1. Aged 60 to 85 years
2. Newly presenting high grade lymphoma presenting as:
2.1 Follicular lymphoma
2.2 Diffuse large cell lymphoma including immunoblastic
2.3 Diffuse mixed cell lymphoma - Lymphoblastic and Burkitt's lymphoma are excluded
3. Stage IB-IV
4. Patients must be free from any other irreversible medical condition that would drastically limit their lifespan or prohibit the use of combination chemotherapy

Participant type(s)
Patient

Age group
Senior

Sex
Not Specified

Target number of participants
Not provided at time of registration

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
01/01/2000

Date of final enrolment
31/12/2005

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
MRC Clinical Trials Unit
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
UK Co-ordinating Committee for Cancer Research (UKCCCR)

Sponsor details
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Sponsor type
Government

ROR
https://ror.org/054225q67

Funder(s)

Funder type
Research organisation

Funder Name
Cancer organisations (UK)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration